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Background: Following Helicobacter pylori eradication in idiopathic parkinsonism (IP), hypokinesia improved but
flexor-rigidity increased. Small intestinal bacterial-overgrowth (SIBO) is a candidate driver of the rigidity: hydrogen-
breath-test-positivity is common in IP and case histories suggest that Helicobacter keeps SIBO at bay.
Methods: In a surveillance study, we explore relationships of IP-facets to peripheral immune/inflammatory-
activation, in light of presence/absence of Helicobacter infection (urea-breath- and/or stool-antigen-test: positivity
confirmed by gastric-biopsy) and hydrogen-breath-test status for SIBO (positivity: >20 ppm increment, 2
consecutive 15-min readings, within 2h of 25G lactulose). We question whether any relationships found between
facets and blood leukocyte subset counts stand in patients free from anti-parkinsonian drugs, and are robust
enough to defy fluctuations in performance consequent on short t½ therapy.
Results: Of 51 IP-probands, 36 had current or past Helicobacter infection on entry, 25 having undergone successful
eradication (median 3.4 years before). Thirty-four were hydrogen-breath-test-positive initially, 42 at sometime
(343 tests) during surveillance (2.8 years). Hydrogen-breath-test-positivity was associated inversely with Helicobacter-
positivity (OR 0.20 (95% CI 0.04, 0.99), p<0.05).
In 38 patients (untreated (17) or on stable long-t½ IP-medication), the higher the natural-killer count, the shorter
stride, slower gait and greater flexor-rigidity (by mean 49 (14, 85) mm, 54 (3, 104) mm.s-1, 89 (2, 177) Nm.10-3, per
100 cells.μl-1 increment, p=0.007, 0.04 & 0.04 respectively, adjusted for patient characteristics). T-helper count was
inversely associated with flexor-rigidity before (p=0.01) and after adjustment for natural-killer count (-36(-63, -10)
Nm.10-3 per 100 cells.μl-1, p=0.007). Neutrophil count was inversely associated with tremor (visual analogue scale,
p=0.01). Effect-sizes were independent of IP-medication, and not masked by including 13 patients receiving
levodopa (except natural-killer count on flexor-rigidity). Cellular associations held after allowing for potentially
confounding effect of hydrogen-breath-test or Helicobacter status. Moreover, additional reduction in stride and
speed (68 (24, 112) mm & 103 (38, 168) mm.s-1, each p=0.002) was seen with Helicobacter-positivity. Hydrogen-
breath-test-positivity, itself, was associated with higher natural-killer and T-helper counts, lower neutrophils (p=0.005,
0.02 & 0.008).
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Conclusion: We propose a rigidity-associated subordinate pathway, flagged by a higher natural-killer count,
tempered by a higher T-helper, against which Helicobacter protects by keeping SIBO at bay.
Keywords: Pathogenesis of Parkinson’s disease, Helicobacter, Small intestinal bacterial overgrowth, Blood leukocytes,
Natural-killer, T-helper, Neutrophils, Hypokinesia, Rigidity, TremorBackground
Milestones in elucidating the aetiopathogenesis of Par-
kinson’s disease have been few and far between. We step
back to consider the whole entity. Constipation featured
in the original description [1]. Frequency of defecation
deviates from that of controls three decades before me-
dian age of diagnosis [2], and infrequent bowel move-
ments are associated with subsequent diagnosis [3].
Abnormal bowel function becomes more apparent post-
diagnosis [2]. In contrast peptic ulceration has pro-
dromal excess [4] and little-in-the-way of local aftermath
[5]. Morphological and neurochemical changes asso-
ciated with Parkinson’s disease are found in the enteric
nervous system of oesophagus, stomach, duodenum and
small- and large-intestine, in coeliac and para-verebral
sympathetic ganglia and dorsal vagal nuclei [6-11]. Mito-
chondrial dysmorphology is seen in duodenal entero-
cytes in idiopathic parkinsonism [12]. This, if replicated
in enteric neurones and/or myocytes, and associated
with dysfunction [13], may provide a mechanism behind
slow gastrointestinal transit.
What initiates and perpetuates slow transit? A viral pri-
mer cannot be excluded [14]: enteroviruses infect via the
gastrointestinal tract and can have neurological sequelae; je-
junal denervation is seen with human immunodeficiency
virus infection, which can cause parkinsonism. In mice,
intranasal inoculation with H5N1 influenza virus resulted
in passage from enteric and dorsal root ganglia to brain
stem. Ascent from here left a trail of microglial activation
and dopaminergic degeneration [15]. Could Helicobacter
pylori, the organism causally associated with peptic ulcer,
affect transit? The H. pylori serum immunoblot antibody
profile predicts abnormal bowel function in probands with
idiopathic parkinsonism and their spouses [12]. In the pres-
ence of an anti-urease-B band, there was a four-fold in-
crease in the odds of having abnormal function,
irrespective of subject-group and urea-breath-test evidence
of current infection. With an outer-membrane protein anti-
body band, there was a six-fold decrement.
Probands with idiopathic parkinsonism, aged ≤72.5 years,
are twice [16], and siblings of probands three-times [17], as
likely as controls to be seropositive for H. pylori anti-urease
antibody. As in peptic ulcer/gastric carcinoma, there is no
birth-cohort effect in antibody titre in probands in contrast
to controls [16]. This is compatible with causality and/or
progressive immunocompromise. In no disease where H.pylori is causal is it present in every case [18]. In Western
populations, follow-up of cohorts tends to demonstrate a
loss of H. pylori. This is generally attributed to widespread
use of antimicrobials and acid-suppressants: low eradication
rates cumulate with repeated exposure. The mainstay of
anti-parkinsonian therapy, dopaminergic precursors, ago-
nists and promoters, act locally and centrally to protect
against experimental ulcers [19-21]. Whether therapeutic
doses of dopaminergic agents suppress Helicobacter has
not been explored, but agonists have been used to prevent
duodenal ulcer relapse [22]. Danish population registers
show increased prescription of Helicobacter eradication
drugs in the 5 years prior to diagnosis of Parkinson’s disease
[23], compatible with prodromal peptic ulcer [4]. Persistent
infection might explain aggressive parkinsonism. Subjective
motor assessment is, indeed, worse, relative to time since
diagnosis, in Japanese probands with H pylori [24]. Parkin-
son’s disease has been linked to rural living and farm ex-
perience [25]. A mortality study of 26 US states found
increased proportional mortality from Parkinson’s disease
among livestock, but not arable, farmers [26]. Zoonotic-
transmission of other gastric Helicobacters may contribute
to the aetiopathogenesis.
H. pylori is an arbiter for progression of brady/hypokinesia
in idiopathic parkinsonism [5,27]. Improvement in gait, in
the year following successful blinded-active anti-H. pylori
treatment [5], was replicated by open-active following initial
placebo-randomisation. Gait plateaued over the subse-
quent two years. Improvement was independent of
whether patients were untreated or receiving stable anti-
parkinsonian therapy (levodopa use excluded to avoid iat-
rogenic fluctuations in performance). The effect is not
related to infection-load: eradicating H. pylori detected
only by molecular microbiology on culture-negative biop-
sies (‘low-density’ colonisation) occasioned similar im-
provement. Marked deterioration accompanied the natural
experiment of eradication failure, even where persistence
was at low-density. All failures were anti-nuclear antibody
(ANA) seropositive. Moreover, ANA-positivity marked a
poorer response to ‘successful’ eradication, perhaps indicat-
ing persistent undetected infection. Furthermore, irrespect-
ive of anti-urease ELISA seropositivity, the H. pylori serum
immunoblot antibody profile against pathogenicity markers
(cytotoxicity-associated gene-A product, vacuolating toxin-
A and urease-B) is predictive of risk, severity and deterior-
ation of idiopathic parkinsonism [28]. The underlying
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immunity is supported by the finding of HLA-DR risk loci
[29,30]. It may have a peripheral (eg. skeletal muscle and
cardiac mitochondria) as well as basal ganglia targets
[12,14].
Improvement in brady/hypokinesia following H. pylori
eradication was mirrored by an increase in objectively-
measured flexor-rigidity: rigidity increased in year one
post-eradication, plateaued over the subsequent two [5]. In
a case study, this increase in rigidity coincided with onset
of hydrogen-breath-test positivity for small intestinal bac-
terial overgrowth (SIBO), rigidity decreasing on regaining
negativity [5]. Overgrowth may drive a subsidiary rigidity-
associated pathogenic pathway, and be a relatively non-
specific and dose-related player in perpetuating neuronal
damage [14,27]. A 54% prevalence of glucose-hydrogen-
breath-test positivity for SIBO is reported in Parkinson’s
disease, versus 8% in controls [31]. Peripheral inflamma-
tion can evade or compromise the blood–brain barrier
[32]. Overgrowth could provide a source of inflammation
over a wide surface area with a strong haematogenous sig-
nal to microglia, as well as an afferent vagal [32]. (Gut-
brain communication still occurs after vagotomy [33].)
Overgrowth is not an innocent bystander in the
gastrointestinal tract: there is bloating and flatulence
[31], and clouds of lysosomes are seen in duodenal
enterocytes in relation to luminal bacteria (unpublished
observation: A. Curry, SMD, RJD, IB). Long thin, often
complex-branching, mitochondria are seen in duodenal
enterocytes [14], rather than the protein arrays encapsu-
lated by a double-membrane associated with H. pylori
[12]. Overgrowth could drive homocysteine production
and increase utilisation of vitamin B12 (a co-factor in
homocysteine detoxification)[27]. Neither hyperhomo-
cysteinaemia (43%) nor serum B12 concentration, in idio-
pathic parkinsonism, is explained by Helicobacter status.
Since slow transit predisposes to reflux of colonic flora
into the small-intestine, SIBO is likely to begin as a sec-
ondary phenomenon, but it may exacerbate gastrointes-
tinal neuronal damage.
Here, we use surveillance data to explore the relation-
ship of different facets of idiopathic parkinsonism to per-
ipheral immuno-inflammatory activation, in the light of
presence/absence of Helicobacter infection or of SIBO.
Do any relationships between facets and blood leukocyte
subset counts stand in patients free from anti-parkinsonian
drugs, and are they robust enough to defy fluctuations in
performance consequent on levodopa therapy? This builds
on our demonstration of biological gradients of objective
measures of facets on two systemic markers of inflamma-
tion, serum cortisol and tumour-necrosis-factor-α [34, 35].
Reale et al. [36] have subsequently shown gradients of glo-
bal scores of function and motor impairment on peripheral
blood mononuclear cell production of cyto/chemokinesand expression of nuclear factor κB. The setting is that,
compared with controls, there is a relative lymphopenia in
idiopathic parkinsonism, with an upward shift in the pro-
portional distribution of natural-killer cells, a downward in
B-cells [27]. T-helper and cytotoxic T-cell distributions are
platykurtic (greater proportions than expected above and
below reference ranges). Neutrophil counts tended to be
higher. These findings were not attributable to anti-
parkinsonian treatment. That of a relative lymphopenia
confirmed previous smaller studies [37-40].
We also explore the relationship between Helicobacter
and hydrogen-breath-test status in idiopathic parkin-
sonism. Gastric pathophysiology, conducive to peptic
ulceration in the prodrome, might protect against col-
onisation of the small-intestine from above: gastrin
secretion, evoked by antral-predominant gastritis,
enhances the acid-barrier. Later, the barrier might be
compromised by cytokine-mediated inhibition (local
or central) of acid secretion [41] or by corporal gas-
tric atrophy. After presentation, any Helicobacter
gastritis is characteristically mild, atrophy absent [5],
but inflammation associated with SIBO, secondary to
caeco-ileal reflux, could progressively inhibit acid,
with suppression of Helicobacter (as seen with proton
pump inhibitors).
Methods
Surveillance data: patients and setting
Fifty-one consecutive patients with ‘clinically-definite’
idiopathic parkinsonism (IP)[42] and taking no or stable
anti-parkinsonian medication were surveyed. The setting
is a ‘gut-brain axis’ clinic, with emphasis on quantifica-
tion of IP-facets to assess disease progression/response
to routine interventions, and incorporating specialist
neuropharmacology, gastrointestinal and immunological
expertise. The sample is comprised of all patients eligible
by the inclusion and exclusion criteria (Table 1). They
were surveyed over a median follow-up of 2.8 (interquar-
tile range 1.0, 3.6) years, limited by introduction of/
change in anti-parkinsonian medication, in response to
the doctor’s perception of the impact of disease on the
patient’s life style and/or at the patient’s request.
Any assessments, blood sampling and breath-tests
during acute inter-current illness were excluded from
the analysis.
Clinical measurements of outcome
The following disease facets are monitored routinely at
each visit:-
Brady/hypokinesia of gait
Distance-time gait indices are obtained using the shoe-
string device, a telemetric method suitable for routine
assessment [43]. Rested patients walk, “at your own
Table 1 Inclusion and exclusion criteria for surveillance
Inclusion
1. Independently-living subjects with clinically-definitea
idiopathic parkinsonism
2. Taking no or stable anti-parkinsonian medication
3. Caucasian with English as first language and living in UKb
Exclusion
1. Secondary parkinsonism, ‘parkinsonism-plus’ syndromes
and other wider clinical entities [70]
2. Clinical depression [71], dementia [72] or other mental illness
3. Other specific neurological condition
4. Inflammatory bowel disease or history of major
gastrointestinal surgery
5. Other progressive or resolving disorders affecting
physical ability or performance, or underlying incapacity
sufficient to prevent assessments (e.g. use of walking aid)
6. Cardiovascular/respiratory symptoms during normal activities
7. UK MRC muscle strength score <4/5
8. Arthropathy, mucsulo-skeletal disorder or overt abnormalities
of, or history of orthopaedic surgery to, joints of spine or
lower limbs
9. Concurrent therapy with drugs which might be
anti-dopaminergic or with hypnotics or sedatives
10. Recent change in life situation (e.g. bereavement or change
in marital status/domicile)
aAny combination of three of the cardinal features: resting tremor, rigidity,
bradykinesia or impairment of postural reflexes. Alternatively sufficient two of
the four features, with one of first three asymmetrical [42]. Responsiveness to
a dopaminergic drug challenge not a requirement.
bTo constrain ethnic and/or geographical influences.
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walk follows 5 min rest. Stride-length and speed are ana-
lysed: values refer to ‘steady-state’, editing out any build-
up at start of walk, tail-off at end. Stride-length usefully
defines treatment effects and, when corrected for rele-
vant demographic/anthropometric characteristics, discri-
minates well between those with and without diagnosed
parkinsonism [44].
Upper limb rigidity
The supported forearm is moved horizontally, at a con-
trolled velocity, through a 40° arc about the elbow [45]. The
side judged more rigid at the initial assessment is moni-
tored throughout. Swing duration is 1.3 s, the pause be-
tween varying (1 to 3 s) to reduce the effect of anticipation.
One minute’s acclimatization precedes 2½ min recording.
A computer interface unit measures the torque required
for passive displacement against position (sampling interval
25 ms). Mean torque for each extending and flexing swing
is calculated, grand means taken for resistance to extension
(termed ‘flexor-rigidity’) and to flexion (‘extensor-rigidity’).
Greater rigidity in flexor than in extensor muscles is
characteristic of parkinsonism.Tremor of hands
A fixed camera films a plan-view of hands, resting semi-
prone on the table in front of the seated patient [5]. It
records any tremor over one minute before, and during,
stress from repeating-back, in reverse order, series of
spoken random-numbers. The archive of surveillance
videos was audited by an independent assessor, blind to
date and treatment, using a visual-analogue scale for
each recording condition. (Scale was from 0, the most
intrusive tremor witnessed between-subject, to 100,
no tremor). Differences in this assessor’s ratings from
those of two others are small (mean 3–6 %) and not
significant [5].
Postural abnormality
Instability at stance is measured by total angular dis-
placement (sway) in the sagittal plane [46]: patients
stand at ease, with eyes open for 1 min, then closed for
3 min. Mean coronal foot-separation at mid-swing, using
the shoestring device, provides an objective measure of
stability during walking [46,47].
Psychomotor ability
Reaction time is measured as time taken to lift left or
right index-finger from its touch-sensitive support [48].
Two seconds before the imperative, an alerting signal
does, or does not, warn whether left or right is to be
lifted. ‘Cognitive efficiency’ is measured by the ratio,
unwarned⁄warned reaction time.
Stance/gait videos
A ‘blinded’ independent auditor analysed anterior and
lateral videos of standing (15 s) followed by walking
(over 12.5 and 6.5 m, respectively). Lateral perspective is
from the side on which rigidity is measured. Scales
(Table 2 footnote) were constructed to describe brady/
hypokinesia, simian and coronal postural abnormalities
(Figure 1) and tremor. (Each scale was from 0, most se-
vere abnormality witnessed in any patient, to 100, nor-
mality). The first three scales took equal account of
items. Each item was composed of correlated groupings
of formulated observations and/or their derivatives
(e.g. inverse of cadence), which contributed equally. The
scale for tremor during stance/walk simply took equal
account of three observations. Observations were scored
against set criteria (median 4 point scale, range 2–10
(derivative, inverse of cadence, excluded)). Chronbach’s
alpha [49] showed satisfactory [50] within-scale consistency
for the 12-item brady/hypokinesia (0.9), 13-item simian
posture (0.7) and 3-observation tremor (0.9) scale.
Consistency was not satisfactory for the 9-item coronal
postural abnormality scale (0.4) overall, no better for its 3
items relating to ‘lower limb alignment’ or 6 relating to
‘head and body asymmetry’.




Demographic Age (years) 65 (48, 81)
Gender (male/female) 32/19a
Height (m) 1.69 (1.51, 1.86)
Weight (kg) 76 (51, 102)









Total white cell count (109/l) 6.4 (3.9, 1.3)
Neutrophils (109/l) 3.8 (1.9, 7.3)
Lymphocytes (109/l) 1.7 (0.9, 3.1)
Mononuclear cell subset (/μl)
T-helper (CD4+) 810 (345, 1903)
T-cytotoxic (CD8+) 392 (118, 1305)
B-cell (CD19+) 170 (44, 657)
Natural-killer (CD16+CD56+) 258 (94, 705)
Brady/
hypokinesia
Mean stride-length (mm) 1199 (795, 1602)
Free-walking-speed (m/s) 1.16 (0.68, 1.64)
Brady/hypokinesia scale
(100 none, 0 worst)d
60 (55, 64)b
Rigidity Mean torque to extend forearm
(Nm x10-3)
589 (206, 1678)e
Mean torque to flex (Nm x10-3) 286 (98, 830)e
Ratio torque to extend/to flex 2.06 (0.80, 5.32)e
Tremor rating Mean tremor whilst seated
(100 none, 0 worst)
92.3 (62.8, 100)b
at rest 100 (73.0, 100)
under stress 90 (50, 100)
Postural
abnormality
Tremor during stance/walk scale
(100 none, 0 worst)f
98.3 (83.3, 100)b
Mean body sway (°/min) 8.5 (3.7, 19.1)e
with eyes open 6.1 (2.2, 17.4)e
with eyes closed 9.2 (4.1, 2.4)e
Mean foot separation (mm) 190 (141, 256)






Mean unwarned reaction time
(ms)
518 (251, 1070)e
Mean warned reaction time (ms) 322 (154, 672)e
Mean arterial
pressure
Supine (mmHg) 95 (66, 123)
Standing: mean over 3 min
(mmHg)
97 (75,119)
Mean pulse rate Supine (/min) 66 (48, 85)
Standing: mean over 3 min
(/min)
75 (54, 95)













cas levodopa combined with extracerebral dopa-decarboxylase inhibitor ±
catechol-O-methyl transferase inhibitor, none receiving combination as
monotherapy. Other anti-parkinsonian medication used [selegiline,
pramipexole, cabergoline, amantadine, trihexyphenidyl (low dose)] at steady
state, and as evenly spaced as practicable with reference to t½, to avoid
iatrogenic fluctuations in performance.
d12 items in scale: overall impression of brady/hypokinesia (4 observations),
speed (3), stride including inverse of cadence (3), flow (2), ability to maintain
‘steady-state’ gait without progressive deterioration (2), symmetry of gait (2),
pelvic swing (2), swing from hips (4), average of knee kick as leg swings past
vertical (4), difference in kick between sides (2), average arm swing (4), and
difference in swing between sides (2).
eExponential of loge transformed data.
f3 observations in scale, all relating to more rigid side: during walk from
anterior perspective and from lateral, and at stance from lateral
g13 items: overall impression of simian tendency (4), festinant gait (2), head
held flexed (3), chin projection (3), dropped jaw (1), hands behind back at
stance (2), flexion at elbow (8), flexion at waist (4), compensatory shoulder
retraction (1), flexion at hips (2), flexion at knees (4), inability to hyperextend
at knee (4) and nature foot strike (4).
h9 items: 3 items for lower limb alignment (bow-legged (2), foot separation
decrease (4), and foot inversion (6)), and 6 items for head and body
asymmetry (body lean to worse side (3), body lean to best (3), shoulder
elevation (3), difference in height of shoulders (2); head over to worse side (2)
and head over to best (2)).
iMedian (interquartile range) 1224 (1011, 2160) days prior to start of
surveillance.
j2 had failed Helicobacter-eradication on urea-breath-test, and were retreated
successfully.
kduring surveillance, 42 were hydrogen-breath-test +ve at some point.
Figure 1 Stickmen representing postural abnormalities in
parkinsonism. Simian (left), with flexion of neck, thoracic and
lumbar spine, hips and knees, and hunched shoulders, is the most
recognised. In coronal (right), there is lateral flexion of body and
related abnormalities.
Dobbs et al. Gut Pathogens 2012, 4:12 Page 5 of 16
http://www.gutpathogens.com/content/4/1/12
Dobbs et al. Gut Pathogens 2012, 4:12 Page 6 of 16
http://www.gutpathogens.com/content/4/1/12Other measurements
Rested supine and standing (immediate and at 1 and
3 min) blood pressure and pulse are measured. Body
weight is measured unshod, without outer clothing.
Unshod height is obtained with buttocks and heels
against a wall, but the patient otherwise relaxed.
Blood cellular profile and autoantibody screen
Initially, a routine full blood count (XE2100, Sysmex UK
Ltd., Wymbush UK), and mononuclear cell subset
counts (FACSCalibur flow cytometer, Becton Dickinson,
San Jose, California, USA, with four-colour fluorescent
cell labelling using MultiTEST kit in TruCOUNT tubes)
are obtained. The sum of the subset counts was vali-
dated by reference to ‘total lymphocytes’ in the full
blood count. Serum is screened for ANA by indirect im-
munofluorescence using Hep2010 cells and rat stomach,
kidney & liver composite tissue block (Euroimmun Bio-
chip slides, Euroimmun UK, Pontypool, UK). Secondary
antibodies are FITC-conjugated polyclonal rabbit anti-
human IgG (Dako, Ely, UK). These standard immuno-
logical procedures are subject to the UK national exter-
nal quality assurance scheme.
Helicobacter status
Initially, Helicobacter status is checked by [13C]urea-
breath-test (INFAI Ltd., York, UK) and/or stool antigen
(Oxoid, Basingstoke, UK) in all patients. Infection is rou-
tinely confirmed by endoscopic-biopsy (with written
informed consent) for histopathology and/or culture,
and, if culture negative, detection of H. pylori-specific
DNA [5]. Eradication therapy consists of one to two
weeks’ proton pump inhibitor, plus two antimicrobials,
selected according to in vitro sensitivities or with refer-
ence to clarithromycin susceptibility determined by mo-
lecular microbiology. Any history of intolerance is taken
into account. Success is judged by the non-invasive tests
at 6 weeks, confirmation by repeat endoscopic biopsy
offered after at least 4 months.
Hydrogen-breath-test status
Small intestinal bacterial overgrowth is screened for by
the lactulose-hydrogen-breath-test in all patients, to
monitor the need for/response to adequate fluid con-
sumption and bulk/osmotic laxatives. A test consists of
measuring breath-hydrogen concentration (Gastrolyser,
Micro Medical Ltd., Rochester, UK) before and after
(15-min intervals for 4 h) 25 G lactulose, following
24-h deprivation of dairy products (and medicinal lac-
tulose) and a breakfast of 250 ml black tea/coffee or
water. Status is defined by whether the meter manu-
facturer’s diagnostic cut–point (20 ppm increment) is
exceeded by two consecutive readings within 2 h [51].
A prolonged test, with non-absorbable substrate, waschosen because of potentially impaired gastric-
empting and intestinal transit [52]. Breath-hydrogen
increases when lactulose reaches the colon, but false
positives due to rapid oro-caecal transit [53] are very
unlikely in IP. Use of glucose risks missing distal
SIBO [54], since it is absorbed proximally.
Statistical methods
Observational data are used to describe patterns of asso-
ciation between disease facets and blood leukocyte sub-
sets. False-positives are not anathema in the structured
approach to hypothesis generation described below, false
negatives are: adjustment for multiple comparisons is
inappropriate.
The association between a cell count and each physio-
logical/cognitive ‘outcome’ measure was assessed in iso-
lation, using a linear mixed effects regression model
with outcome measure as dependent variable and cell
count as independent. Account was taken of dependen-
cies due to the physiological outcome being measured
longitudinally: a random intercept was generated for
each patient by inclusion of a patient random effect in
the regression model. In contrast, cell counts and poten-
tial demographic covariates were taken to be invariable
and measured once at the beginning of surveillance.
The regression analysis was first targeted at a ‘core group’
of 38 probands receiving no anti-parkinsonian medication,
or medication other than levodopa. Independent variables,
for which evidence of an association could not be dis-
counted in the single variable analysis (p<0.2), were
included in multivariable linear mixed models. A backwards
elimination process was used to remove, in turn, the least
significant independent variable, until all remaining exhib-
ited a statistically important association. Discarded variables
were then each included separately into the resultant multi-
variable model to ensure that their lack of association
remained true. Cellular associations with outcome of
p-value ≤0.05 were considered to be ‘statistically sig-
nificant’. A between-subject analysis, using the aver-
age outcome measure in each patient, was used to
substantiate associations of outcome measure and
cell count, but sizes of effect given refer to the longi-
tudinal multivariable models. (Estimated regression
lines shown are from analyses which include all
values for a longitudinal outcome, although, for pres-
entation purposes, the points are restricted to an
average per person.) Surrogacy of inter-related out-
come measures in explaining cellular associations
was examined. Longitudinally-assessed Helicobacter
and hydrogen-breath-test status was included in the
final models to determine whether they might ex-
plain any associations between outcome and cell
count. Multivariable models were fitted in the 17 ‘un-
treated’ patients alone and in the ‘entire’ group of 51
Figure 2 Relationship between breath-hydrogen concentration
and blood leukocyte subsets over time after lactulose
administration. Average increase in breath-hydrogen over baseline
(343 tests; 15 min sampling intervals over 4h) is standardised for
leukocyte count. Test positivity in the first 2h was associated with
higher natural killer and T-helper mononuclear counts, lower
neutrophils. Subsequently, breath-hydrogen was associated with
T-helper count, tended to be with natural-killer (3 (95% CI 0, 4) & 5
(0, 11) ppm per 100 cell.μl-1 increment, respectively, p=0.02 & 0.06),
but was not associated with neutrophil.
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levodopa) to assess the consistency of associations in
these contexts.
Similarly, single variable analysis and multivariable
generalised linear mixed modelling were used to assess
associations between hydrogen-breath-test status and
cell counts.
A natural logarithmic transformation to approximate
‘Normality’ was performed on variables with a positively-
skewed distribution. Assumptions of Normally distributed
random effects and residuals were checked graphically
using normal quantile plots. Combined scaled measure-
ments obtained from videos had approximately Normal
distributions.
Results
Characteristics of patients with idiopathic parkinsonism
Table 2 gives baseline demographic and haematological
data, outcome measures, and status with respect to Heli-
cobacter and hydrogen-breath-test for the entire group.
Hydrogen-breath-test positivity was associated in-
versely with Helicobacter positivity (OR 0.20 (95% CI
0.04, 0.99), p=0.05). Hydrogen-breath-test positivity was
unrelated to receipt of anti-parkinsonian medication
other than levodopa, but directly associated with
levodopa receipt (3.50 (1.01, 12.14), p=0.05).
Cellular association with breath-hydrogen
Of the entire group, 67% were classified as positive on
the basis of the first 2 h of the initial hydrogen-breath-
test, 82% being positive at some point during surveil-
lance. Positivity was not associated with total lympho-
cyte, cytotoxic T-cell or B-cell counts, but with higher
natural-killer (CD16+56+) (p=0.01) and T-helper (CD4
+) (p=0.05) counts, and a lower neutrophil polymorpho-
nuclear leukocyte count (p=0.02). Our multivariable
explanation contained these (odds ratios for positivity:
1.7 (95% CI 1.2, 2.5) & 1.2 (1.0, 1.3) per 100 mono-
nuclear cells.μl-1 increment, respectively; 0.65 (0.48,
0.89) per 109 neutrophils.l-1, p=0.005, 0.02 & 0.008) and
age (p=0.04). Figure 2 shows that the association of
breath-hydrogen with T-helper count is sustained to 4 h.
That with natural-killer count tended to be, but the neu-
trophil association was lost.
Cellular associations with clinical measurements
We present associations, meeting the set criteria, of
leukocyte subsets implicated above (first natural-killer, sec-
ond T-helper, third neutrophil), followed by any associa-
tions of other subsets studied (total lymphocyte, cytotoxic
T-cell or B-cell), with:-
Brady/hypokinesia and rigidity. In the core group of
38 patients (untreated plus those receiving anti-
parkinsonian medication other than levodopa), singlevariable analysis revealed significant relationships of
natural-killer count to mean stride-length, free-walking-
speed and flexor-rigidity (p=0.007, 0.02 & 0.02): the
higher the count, the worse the facet. Size of effect
remained clinically important after correction for rele-
vant demographic covariates (Additional file 1: Table S3,
Part a, Figure 3). Count was not related to extensor-
rigidity or to the difference, flexor minus extensor. The
association of natural-killer count with brady/hypokine-
sia was even captured from video by the brady/hyoki-
nesia scale (Figure 3), just as were the additional effects
of medication status and time since diagnosis (p=0.01 in
each case).
T-helper count ‘modulated’ the effect of natural-killer
count on rigidity (the higher the count, the less rigidity),
but did not contribute to the explanation of brady/hypo-
kinesia by natural-killer count. It was associated with
flexor-rigidity both before (p=0.01) and after adjusting for
natural-killer count and covariates, with extensor only
after covariate adjustment (Figure 4).
Mean stride-length and free-walking-speed were highly
associated, flexor- and extensor-rigidity less tightly so,
whilst stride showed no association with flexor- or
extensor-rigidity under the test conditions (Figure 5).
Accordingly, the association of stride with natural-killer
count was not confounded by including flexor-rigidity in
the multivariable model, nor were those of flexor-rigidity
with natural-killer and T-helper counts confounded by
including stride-length. Cellular associations held after
allowing for the potentially confounding effect of
Figure 3 Relationship of brady/hypokinesia and flexor-rigidity to natural-killer count in core group, after adjustment for demographic
characteristics and, in the case of flexor-rigidity, for T-helper count. (Standardised, as appropriate, to no background medication, age 65
years, height 1.7 m, time since diagnosis 6 years, T-helper count 1000 μl-1.) Regression line and 95% CI are shown for stride-length, free-walking-
speed, the brady/hypokinesia scale and flexor-rigidity on natural-killer count. Although all values for a longitudinal outcome were used to
estimate regression lines, the points shown are the average per person. (Brady/hypokinesia scale: 0 = marked impairment on video, 100 = none).
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http://www.gutpathogens.com/content/4/1/12hydrogen-breath-test or Helicobacter status. Helicobacter
positivity was, however, associated with an additional
shortening of stride and reduction in speed (by 68 (24,
112) mm & 103 (38, 168) mm.s-1 respectively, p=0.002
in each case), but it had no effect on rigidity.
Associations with cell counts remained after adjustment
for presence/absence of anti-parkinsonian medication inFigure 4 Relationship of rigidity to T-helper count in core group, afte
flexor-rigidity, for natural-killer count. (Standardised, as appropriate, to t
250 μl-1.) Regression line and 95% CI are shown for flexor- and extensor-rigthe core group (Additional file 1: Table S3, Part a). Indeed,
size and significance of effects were retained in the un-
treated group (Additional file 1: Table S3, Part b). In the
entire group, which included patients receiving levodopa,
size of effect of natural-killer count on objective measures
of brady/hypokinesia was similar to that in the core
(Additional file 1: Table S3, Part c), definition of effect onr adjustment for demographic characteristics, and, in the case of
ime since diagnosis 6 years, body weight 80 kg, natural-killer count
idity on T-helper count.
Figure 5 Relationship, in core group, of hypokinesia (stride-length) to bradykinesia (speed) and flexor-rigidity to extensor, and
independence of hypokinesia from rigidity. No adjustment is made for demographic covariates. Regression line and 95% CI are shown for
stride on speed (upper left graph - point with co-ordinates of stride 378 mm & speed 0.3 m.s-1 not influential); flexor-rigidity on extensor (upper
right); stride on flexor-rigidity (lower left); stride on extensor-rigidity (lower right - after removal of an influential point: co-ordinates stride 378 mm
& rigidity 990 Nm.10-3).
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http://www.gutpathogens.com/content/4/1/12stride sharper in the core. Both size of effect and signifi-
cance of the association between natural-killer count and
flexor-rigidity were lost in the entire group. Those of T-
helper count with both flexor- and extensor-rigidity were as
strong as in the core. It should be noted that levodopa was
not used as first-line treatment: stride tended to be shorter
(by 128 (268, -12) mm, p=0.07) in those receiving it, rigidity
was similar.Figure 6 Relationship of supine mean arterial pressure to
natural-killer count in core group, after adjustment for
demographic covariates (standardised to age 65 years, time
since diagnosis 6 years, body weight 80 kg). Regression line and
95% CI are shown. On inclusion of flexor-rigidity in multivariable
model, cellular association remained 3.4 (0.4, 6.5) mmHg per 100
cells.μl-1 increment, p=0.03), and an additional small effect on
pressure was seen (increase of 3.4 (0.8, 6.0) mmHg per 500 Nm.10-3
greater rigidity, p=0.01).Mean arterial pressure
Hypotension is a feature of idiopathic parkinsonism.
However, in the core group, single variable analysis
revealed a significant relationship of natural-killer count
to supine mean arterial pressure (p=0.02): the higher the
count, the higher the pressure. This effect remained after
correction for relevant demographic covatiates (Add-
itional file 2: Table S4, Part a, Figure 6). Its magnitude
was equivalent to the predicted increase in pressure with
10 years of age or 10 kg of body weight, or decrease over
4 years from diagnosis. The association of natural-killer
count with pressure was not a surrogate for that with
brady/hypokinesia or flexor-rigidity. Any association be-
tween cellular profile and standing pressure wasmasked by variability in orthostatic response (mean
difference from supine −4 (data interval −18, 10)
mmHg).
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not confounded by hydrogen-breath-test or Helicobacter
status. Neither status had an additional effect on pres-
sure. Size of effect of natural-killer count on pressure
was independent of anti-parkinsonian medication in the
core group, similar in the untreated and entire (Add-
itional file 2: Table S4, Parts a, b and c). However, in the
untreated, it did not reach statistical significance.
Tremor
In the core group, single variable analysis revealed a sig-
nificant relationship of neutrophil count to the mean score
for tremor whilst seated (p=0.03): the lower the count, the
greater the tremor. This small but significant effect
remained after correction for the relevant demographic
covariate, time since diagnosis (Additional file 3: Table S5,
Part a, Figure 7), and was independent of condition, rest
or stress. Its magnitude was equivalent to the predicted in-
crease in tremor with 5 years’ time lapse. One might ex-
pect a stiff arm to tremble less. Indeed, although rigidity
held no surrogacy for tremor in the neutrophil association,
flexor-rigidity tended to have an additional effect on
tremor: the greater the rigidity, the less the tremor (by 3
(95% CI 0, 6) units per 500 Nm x10-3, p=0.09).
The neutrophil association with tremor was not con-
founded by hydrogen-breath-test or Helicobacter status.
However, Helicobacter positivity had an additional effect:
tremor was less with positivity by 6.3 (0.5, 12.2) units
(p=0.03). Size of effect of neutrophil count on tremor
was independent of anti-parkinsonian medication in the
core group, retained in the untreated and not masked in
entire (Additional file 3: Table S5, Parts a, b and c).
However, in the untreated, it reached significance only at
the 0.1 level.Figure 7 Relationship of mean tremor whilst seated to
neutrophil count in core group, after adjustment for time since
diagnosis (to 6 years). Regression line and 95% CI are shown.
Outlier for neutrophil count (9.48 x109.l-1) not influential (size of
effect after exclusion: decrease in tremor of 7.9 (95% CI 1.3, 14.5)
units per 109.l-1 cell increment, p=0.02). Tremor scale: 0 = most
intrusive, 100 = no tremor (N.B. 3 values >100 (i.e. 101, 103, 108)
consequent on adjustment for time since diagnosis).No cellular association was seen with postural tremor
while standing and walking, the neutrophil association
with seated tremor remaining after including postural
tremor in the model.
Postural abnormality
There is a case for a B-cell (CD19+) association with
posture ratings, but it falls short of the set criteria.
Simian posture score showed a significant association
with B-cell count in the core group, only after adjust-
ment for time since diagnosis: the higher the count,
the better posture (by 2.1(0.1, 4.1) units per 100
cells.μl-1 increment, p=0.03). Size of effect is set in
context by a 25 to 75th centile range from just 76 to
87. The strength of the cellular association with
simian posture (p=0.01, after adjustment for hypoki-
nesia and rigidity (see Figure 8 legend)) was not con-
founded by incorporating coronal posture into the
model (p=0.004). Size and significance of effect were
retained in entire group, lost in the relatively small
untreated group.
Single variable analysis did reveal a relationship of B-
cell count to coronal posture rating (p=0.05): the higher
the count, the better posture. Significance was similar
(p=0.06) after correction for relevant covariates, time
since diagnosis and weight. Rigidity held no surrogacy
for coronal posture in the B-cell association, but its in-
clusion did have a small additional effect (p=0.001): the
greater extensor-rigidity, the worse posture. Size of effect
was retained in untreated (p=0.1), and entire (p=0.07)
groups.
Neither hydrogen-breath-test nor Helicobacter status
held surrogacy for the B-cell associations or had any
direct effect on posture ratings. No cellular association
was identified for objective assessments of standing body
sway and ambulatory foot separation on single variable
analysis.
Lack of association with psychomotor ability
There was no single variable association of reaction time
(mean of unwarned and warned) or cognitive efficiency
with any of the leukocyte subsets.
Overview of surveillance tools
Figure 8 gives an empirical overview of inter-relationships
of the outcome measures between patients, using
single-variable analysis.
Three cardinal signs, brady/hypokinesia, rigidity and
tremor, are independent of each other under test condi-
tions. The direct relationship between mean stride-
length and free-walking-speed is close, as is that between
tremor measured whilst seated and during stance/walk.































Figure 8 Between-patient relationships of clinical surveillance tools in core group. Outcome measures are represented by discs. Single
variable associations, of strength p≤.05, are represented by lines ending at corresponding disc perimeters. The closer the discs, the more variance
explained: line length is inversely proportional to variance in one outcome explained by the other. Relationships resting on influential points, or
not holding in mixed-effects models, were dismissed. Absence of connecting lines means lack of association. Greatest variance represented by a
connecting line between a pair of outcomes (78%) is for free-walking-speed and mean stride-length, least (13%) for reaction time and speed.
Variance explained by multiple associates can, of course, be cumulative (e.g. variance in simian posture rating explained individually by flexor-
and extensor-rigidity, stride and speed is 30, 53% 40% & 40%, respectively, but together they explain 68%). Principle component analysis of 13
items making up simian posture scale indicated a first component, average score for 9 items, with a greater within-scale consistency than the
original (Chronbach’s alpha 0.8 cf 0.7), and retaining association with brady/hypokinesia and rigidity. Other components could not be interpreted
simply in terms of remaining items: 3 compensatory strategies (chin projection, hands behind back at stance, shoulder retraction), and dropped
jaw. These were not associated with brady/hypokinesia and rigidity, and showed no association inter se.
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tremor, the greater the sway. Ambulatory coronal foot
separation has a moderate association with brady- and
hypo-kinesia: the narrower the separation, the worse
gait. Simian posture rating is moderately related to
brady- and hypo-kinesia, and to rigidity: bad posture
goes with poorer gait and worse rigidity. Cognitive effi-
ciency shows a weak direct association to stride and
speed, reaction time a weak inverse association with
speed: good psychomotor performance under test condi-
tions is reflected in gait.
Supine mean arterial pressure stands independent of
the other outcomes.
Helicobacter infection and small intestinal bacterial
overgrowth in spouses
Spouses of 15 patients had requested screening for
Helicobacter and SIBO: two-thirds (67 (exact binomial
95% CI 38, 88) %) were hydrogen-breath-test positive.
One of these and two of the negatives were urea-
breath-test positive.
Discussion
Here we focus on the aftermath of H. pylori infection. In
the gut/brain axis clinic, nearly three-quarters of the IP-
patients surveyed had evidence of current or past infection
on entry. Half had undergone successful eradication, a
median of 3 years before. Two-thirds were lactulose-
hydrogen-breath-test positive initially, four-fifths at some
time during surveillance.Our approach to aetiology/pathogenesis is to start
from clinical clues. Statistical modelling of observational
data is used to generate hypotheses. Having found sub-
jective global clinical scores to be blunt instruments
[55], we have embraced valid, sensitive, specific and reli-
able measures of disease facets. To avoid incorrect
inferences, we endeavour to understand what is being
measured, its variability and what influences it (i.e.
confounding influences and bias), and explore effect
modification (by interaction or directly). Use of
objective measures brings economy of sample size.
The pattern of cellular associates reported empha-
sises that facets may have different, non-coincident
driving forces.
Biological gradients
Bradford Hill [56] wrote “The clear dose–response curve
admits of a simple explanation”, causality. “Often the diffi-
culty is to secure some satisfactory quantitative measure of
the environment which will permit us explore this dose–re-
sponse.” We identify biological gradients of facets of IP on
blood leukocyte subset counts, and find the same group of
subsets linked to SIBO. The simplest biologically plausible
explanation is that the counts represent driving/ameliorat-
ing forces on the facets, and that SIBO is their source. The
‘Bradford Hill predicament’ is to secure which components
and/or associates of SIBO might affect the inflammatory re-
sponse. However, a complex causal pathway does not pre-
clude interim clinical solutions. In IP, hydrogen-breath-test
positivity indicates the need to assess faecal overload,
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propriate, to institute adequate fluid consumption and
bulk/osmotic laxative therapy. Re-accumulation of overload
is likely: enterokinetic agents have a potential role, particu-
larly if the colon is dyskinetic with an element of retrograde
propulsion [57].
Outcome associations with three leukocyte subsets
withstood rigorous statistical criteria. Under test condi-
tions, three facets were associated with natural-killer cell
(CD16+56+) count: brady/hypokinesia, flexor-rigidity
and higher mean arterial pressure. A higher count may
be accompanied by higher serum cortisol [34] with fluid
retention, whereas (orthostatic) hypotension would be
expected from ‘cold’ degeneration of sympathetic ganglia
and brain stem noradrenergic nuclei. T-helper (CD4+)
count was associated inversely with flexor-rigidity, neu-
trophil count inversely with tremor, as if mounting these
immune responses were protective. Associations were
independent of anti-parkinsonian medication.
In IP, SIBO has systemic consequence. Moreover, the
above three out of the six leukocyte categories studied
(total lymphocytes and neutrophils from full blood
count; CD4+, CD8+, CD19+ and CD16+56+ mono-
nuclear subsets) were associated with hydrogen-breath-
test positivity, suggesting a mechanistic link. Hydrogen-
breath-test status did not per se account for leukocyte
associations with disease facets. Other measures of
SIBO, a component or non-bacterial associate of SIBO,
or imbalance in intestinal microbiota might. Hydrogen-
breath-test positivity, like severity of IP manifestations,
was related to higher CD16+56+ count and lower neu-
trophils, but, unlike severity, to a higher CD4+ count.
The CD4+ subset includes regulatory T-cells which can
inhibit effector mechanisms of natural-killer cells. A
single rigidity-provoking taxon might evoke an increase
in CD16+56+ count, a decrease in CD4+. For example,
escape [58] of a viral cause of slow transit may cause an
increase in CD16+56+ count and, were it lymphotropic,
suppression of CD4+. Alternatively, different compo-
nents/associates of SIBO, with different cellular responses,
might have opposite effects on rigidity.
Breath-hydrogen concentration from 2 to 4 h after lac-
tulose reflected the earlier T-helper and natural-killer
count associations, but not the neutrophil. Chronic bac-
terial overload may suppress neutrophils, overload in the
more distal small-intestine not having the same capacity
to suppress neutrophils as that in the proximal. A degree
of immune tolerance to refluxed colonic microbiota
might be acquired.
Definition of phenotype
The independence of the measures of brady/hypokinesia,
rigidity, tremor and mean arterial pressure described
provides a foundation on which to build a widerdescription of IP. Further measures should be comple-
mentary, not congruous.
It is remarkable that the relationship between natural-
killer cells and brady/hypokinesia was robust enough to
be captured by video assessment. However, the brady/
hypokinesia scale becomes redundant in the face of
rapid objective quantification. Focusing, in a formal
protocol, on tremor whilst seated captured the neutro-
phil association, observing incidental tremor during
walking did not. Although both simian and coronal pos-
ture ratings tended to capture a B-cell association, they
were unrelated in single variable analysis. The associ-
ation with simian posture persisted after large scale ad-
justment for rigidity (on the worse side) and brady/
hypokinesia. Bilateral quantification of rigidity is a next
step towards better definition of these B-cell associa-
tions. Coronal postural abnormality is a manifestation of
disease asymmetry and compensation for this.
Assimilation of findings into potential pathogenic
pathways
To consider causality in terms of single question steps,
arising in unique linear order, denies the multi-step,
multi-factorial nature of chronic disease. Not until a
large number of observational and interventional find-
ings have been assimilated will their position within the
causal pathway become more certain. It cannot be
assumed that disease facets will progress in parallel. The
goal is stratification of pathogenic pathways into those
central to disease initiation and the subsidiary, which
may/may not be activated.
Our work (Table 3) points to three pathogenic path-
ways:- (i) A brady/hypokinetic response to Helicobacter
infection [5]. (ii) A rigidity-associated pathway, linked
directly to natural-killer count, inversely to T-helper. (iii)
A tremor-associated pathway linked inversely to neutro-
phil count. Brady/hypokinesia appears to have two patho-
genic components: its association with Helicobacter
positivity was additional to that with natural-killer count.
Evidence for a fourth pathway does fall short of our
rigorous statistical criteria, but better posture with a
higher B-cell count suggests disease attenuation in
the immunocompetent.
The seemingly self-perpetuating microglial activation
of IP [59] may actually be a response to a continuous
stimulus, commonly SIBO. This does not exclude ex-
acerbation by other inflammatory stimuli. Patients fre-
quently report transient worsening of parkinsonism with
intercurrent illness/its treatment. Moreover, the adaptive
immune response in substantia nigra in Parkinson’s dis-
ease [60], and the presence of peripheral immune cells
(as well as Lewy bodies) in therapeutically-useful dopa-
mine cell brain implants [61], fit with a peripheral
immune process driving neuronal damage.





H. pylori infection Double-blind, placebo-controlled,
randomised efficacy study of eradication.
Differential effects with improvement in hypokinesia and worsening rigidity over
year post-eradication and subsequent (2-year) plateau. Overall: net improvement [5].
Surveillance (i) Detrimental effect of Helicobacter positivity on hypo- and bradykinesia (adjusted
for natural-killer count) [Results: Cellular associations with clinical measurements].
(ii) Improvement in hypokinesia followed Helicobacter-eradication, but not




Surveillance (i) Same three leukocyte subset associated with hydrogen-breath-test positivity and
facets (biological gradient of rigidity on natural killer and T-helper counts; brady/
hypokinesia on natural killer; tremor on neutrophil) [Results: Cellular association with
breath-hydrogen & Cellular associations with clinical measurements].
(ii) Increased rigidity followed antimicrobials for indications other than Helicobacter
(i.e. not indication-specific), suggesting alteration in intestinal microbiota as a player [73].
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hydrogen-breath-tests using different substrates, lactu-
lose and glucose. The slightly lower prevalence of
positivity using the absorbable sugar [31] may repre-
sent missed distal colonisation. We demonstrate an
inverse association between hydrogen-breath-test and
Helicobacter status. Since H. pylori is usually acquired
in infancy, it is reasonable to postulate that any pro-
tection is by Helicobacter against SIBO. Whether the
acid barrier and/or immune regulation determine
such protection needs elucidation. The stability in
anti-parkinsonian medication status over the surveil-
lance period (median 2.8 years) may be a conse-
quence of H. pylori eradication and attenuating SIBO
by maintaining gastrointestinal transit.
Our usage of levodopa (as an adjuvant where func-
tional impairment no longer responds adequately to
other anti-parkinsonian medication) was associated
with hydrogen-breath-test positivity. Meeting our in-
dication for levodopa might coincide with worsening
constipation [2], with more caeco-ileal reflux. Indeed,
in a group of patients exposed only to levodopa
combinations [31], hydrogen-breath-test positivity
was linked to functional staging and severity, with no
additional effect of levodopa dosage (average 800
mg/day).
Dopaminergic status as a determinant of immune
response
It might be argued that the cellular associations with
facets of parkinsonism simply reflect the influence of
dopaminergic status on leukocytes. Dopamine has been
implicated in immunoreguation [62,63]. Its receptor
densities differ between leucocyte subsets and exposure
to dopamine affects the subsets differently. Overall,
dopamine appears to increase natural-killer activity,
and inhibit T-lymphocyte and neutrophil function.Thus, the leukocyte subset count associations with
facets of IP do not fit with surrogacy of cell function
for dopaminergic status, even were count assumed to
represent function.
Crucial future directions
An association of non-H. pylori gastric Helicobacters
with IP [64] would have profound implications as to
whether classical autoimmunity or pattern-recognition
cross-reactivity is involved in the pathogenesis. Classical
autoimmunity may be confined to particular strains
within a bacterial species, whilst pattern recognition
tends to be shared at genus level.
Whereas spouses of IP-patients have been used as
controls, we find they are an important source of patho-
genic clues [27,44]. The prevalence of hydrogen-breath-
test positivity in spouses was similar to that in IP-
patients. Although the number tested was small, it is be-
yond the balance of probability that the prevalence in
spouses is less than 38%. Replication would bring under-
standing the spouses’ predisposition to the fore in un-
ravelling environmental causality.
More detailed observational work on slow transit,
faecal impaction, gut microbiota, and understanding
the immune response of the gut (which contains
“70% of the immune system” [65]) could identify new
targets and strategies to influence disease progression.
Cultural approaches to the gut microbiota are being
superseded, as research tools, by metagenomic mo-
lecular microbiology. This has already defined pat-
terns of stool microbiota (enterotypes) in the
population and indicated changes in the spectrum in
inflammatory bowel disease [66-68]. These changes
include under representation of Gram positive anae-
robes (a major component of faecal microbiota in
health), which inhibit nuclear factor κB-related proin-
flammatory cytokine expression [66] and can
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and autoimmunity [69]. The loss may be counterba-
lanced by increased representation of Gram negative
bacteria expressing pro-inflammatory molecules, like
lipopolysaccharide. Resort to aspiration, brushings or
biopsy may be necessary to characterise proximal and
distal overgrowth. Further work could, by defining the
enterotype in IP with and without Helicobacter, home
in on candidate drivers of systemic inflammatory
activation leading to neuronal damage.
Conclusion
With respect to Hill’s [56] classic attributes of a causal
relationship, we have a coherent, hierarchical and
biological-plausible scheme for the pathogenesis of idio-
pathic parkinsonism, with biological gradients and a pro-
posed time sequence of events. Interpretation may be
wrong in parts, due to real gaps in knowledge or lack of
awareness of alternative explanations. However, the
overall thrust gives new insights into potentially-
remediable pathogenic influences. Hill’s attributes of a
causal relationship also include strength of key associa-
tions expressed as relative risk or odds ratios, experimen-
tal evidence and analogies. These are well represented in
the work-up. His attribute of consistency through repeti-
tion by different groups, in a range of locations selected to
test robustness, needs addressing. That of specificity ‘in
cause’ should be treated cautiously, since the scheme
evokes more than one driving factor. Moreover, speci-
ficity may be masked, in a disease with a long pro-
drome, by classifying as ‘unaffected’ or true negatives
those progressing towards the diagnostic threshold
[17,27,44] and/or in whom the causal factor will first
manifest as another condition (eg. prodromal peptic
ulceration in IP).
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